OPEN ACCESS pISSN 2234-3806
eISSN 2234-3814

Table. 1.

Table. 1.

Clinical characteristics of 367 patients with CH

Clinical characteristics All patients (N=367) Male (N=196) Female (N=171) P
Gestational (weeks) 39.0 ± 0.3 (54) 38.5 ± 0.5 (23) 39.4 ± 0.3 (31) 0.177
Birth weight (kg) 3.3 ± 0.1 (55) 3.3 ± 0.1 (22) 3.3 ± 0.1 (33) 0.241
Birth length (cm) 50.1 ± 0.2 (52) 50.1 ± 0.3 (22) 50.1 ± 0.2 (30) 0.547
Age at diagnosis (days) 20.1 ± 1.0 (190) 20.9 ± 1.5 (102) 19.2 ± 1.2 (88) 0.708
Initial dose (μg)* 30.3 ± 1.2 (94) 29.1 ± 1.8 (38) 31.1 ± 1.6 (56) 0.453
Severity classification 0.445
Mild 113 (50.9%) 58 (48.7%) 55 (53.4%)
Moderate 54 (24.3%) 33 (27.7%) 21 (20.4%)
Severe 55 (24.8%) 28 (23.5%) 27 (26.2%)
Thyroid morphology 0.227
Normal 84 (80%) 39 (86.7%) 45 (75%)
Goiter 5 (4.8%) 1 (2.2%) 4 (6.7%)
Orthotopic hypoplasia 15 (14.3%) 4 (8.9%) 11 (18.3%)
Ectopy 1 (1.0%) 1 (2.2%) 0 (0.0%)
Biochemical tests at diagnosis
FT3 (pmol/L) 4.87±0.12 (222) 4.96±0.15 (119) 4.77±0.19 (103) 0.274
FT4 (pmol/L) 10.55±0.45 (222) 10.40±0.59 (119) 10.73±0.70 (103) 0.749
TSH (μIU/mL) 77.57±4.18 (228) 77.09±6.17 (122) 78.12±5.54 (106) 0.631

*Dose of levothyroxine administered for the first time after the diagnosis of CH. Data are shown as N (%) or mean±SE. The exact number of patients in each group is shown in parentheses after mean±SE.

Abbreviations: CH, congenital hypothyroidism; FT3, free triiodothyronine; FT4, free thyroxine; TSH, thyroid-stimulating hormone.

Ann Lab Med 2024;44:343~353 https://doi.org/10.3343/alm.2023.0337

© Ann Lab Med